Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin and BeiDouGen for PCOS Pregnancy Outcomes
NCT06587698Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Aug 2024
- Primary completion
- Jul 2028
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, open-label trial of sitagliptin and beidougen in polycystic ovary syndrome (PCOS) (3 arms), sponsored by Peking University Third Hospital. Primary endpoint: Clinical pregnancy rate at 2 years. Started Aug 2024; status: recruiting.
02
Drugs
sitagliptinbeidougen
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT06587698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06587698.